Bahrain, Kuwait approve Sotrovimab for emergency use in treating COVID-19

Bahrain, Kuwait approve Sotrovimab for emergency use in treating COVID-19

Saudi Gazette report MANAMA/KUWAIT “” Bahrain and Kuwait on Wednesday approved Sotrofimab for emergency use, a new drug by GlaxoSmithKline (GSK) for the treatment of COVID-19, official news agencies of both countries reported. Earlier this week, the United Arab Emirates gave Sotrofimab a go-ahead for the treatment of COVID-19, becoming the first country in the world to approve the drug for emergency use following the US Food and Drug Administration's approval In a statement carried by the Bahrain News Agency (BNA), Bahrain's National Health Regulatory Authority (NHRA) said that its decision to add Sotrofimab to COVID-19 treatment protocols follows emergency use approval by the FDA as well a comprehensive review of GSK's clinical trials. "Sotrovimab-VIR-7831“ develops "monoclonal antibodies“ and will be used to treat infected adults and adolescents with mild to moderate COVID-19 symptoms who are at risk of their condition deteriorating and resulting in hospitalization, the NHRA said in the statement. According to the BNA report, safety and efficacy evidence demonstrates a reduction in the number of cases requiring hospitalization for more than 24 hours and a reduction in the number of fatalities by 85 percent, when administered at an early stage of treatment. Meanwhile, the Kuwaiti health ministry